ImmunoPrecise, Zymeworks partner on SARS-CoV-2 antibody
September 17, 2020 -- ImmunoPrecise and Zymeworks have announced that they have formed a research collaboration to develop a multispecific SARS-CoV-2 antibody.
Lykan opens manufacturing facility for cell therapies
September 17, 2020 -- Lykan Bioscience has opened a new, 64,000-sq-ft "smart" manufacturing facility in Hopkinton, MA.
Moderna, Vertex collaborate on gene editing therapies for cystic fibrosis
September 17, 2020 -- Moderna and Vertex Pharmaceuticals have entered a three-year research collaboration for the discovery and development of lipid nanoparticles and messenger RNAs for the delivery of gene editing therapies for the treatment of cystic fibrosis.
Amgen, Eli Lilly to scale up manufacturing of COVID-19 antibody therapies
September 17, 2020 -- Eli Lilly and Amgen will collaborate on global antibody manufacturing to significantly increase the supply capacity of Lilly's potential COVID-19 therapies.
Agilent offers new flow cytometers
September 17, 2020 -- Agilent Technologies has launched a new product offering, the Agilent NovoCyte Penteon, a flow cytometer with five lasers and up to 30 fluorescence channels.
AVM Bio to begin trial of COVID-19 immunotherapy
September 16, 2020 -- AVM Biotechnology received authorization for an investigational new drug application from the U.S. Food and Drug Administration to evaluate its proprietary drug, AVM0703, in the treatment of acute respiratory distress syndrome mediated by COVID-19 or influenza patients.
Clinical test allows patients to be directly matched to clinical trial
September 16, 2020 -- Ashion Analytics has partnered with Elevation Oncology to match patients harboring an NRG1 gene fusion identified with Ashion's Gem Extra test with a phase II clinical study of seribantumab, an investigational monoclonal antibody treatment for advanced solid tumors.
Pfizer begins phase I study of COVID-19 drug targeting main protease
September 16, 2020 -- Pfizer has begun a phase Ib clinical trial to evaluate the safety of an investigational COVID-19 drug candidate, PF-00835321, that blocks the main protease SARS-CoV-2 enzyme.
Yufan, Abound Bio to develop CAR-T cell therapies
September 16, 2020 -- Yufan Biotechnologies and Abound Bio have signed a multiyear agreement to find antibodies to direct chimeric antigen receptor-T (CAR-T) cells against cancer targets.
Eli Lilly rolls out early COVID-19 antibody trial data
September 16, 2020 -- Eli Lilly released early data from a phase II clinical trial that explored the use of the neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting.
Conferences
ESMO Virtual Congress 2020
September 14-29
Online
2020 ACCP Annual Meeting
September 20-22
Online
BioProcess International West
September 21-25
Online
BioProcess International
September 21-25
Online
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter